, Volume 37, Issue 6, pp 2116–2124 | Cite as

Preventive Effect of Chrysin on Bleomycin-Induced Lung Fibrosis in Rats

  • Talat KilicEmail author
  • Osman Ciftci
  • Asli Cetin
  • Hasan Kahraman


The aim of the current study is determination of protective effect of chrysin (CRS), a natural flavonoid, on cell injury produced by lung fibrosis induced with bleomycin (BLC) in rats. Twenty-eight female rats were assigned to four groups as follows: control group, CRS group; 50 mg/kg CRS was continued orally for 14 days, BLC group; a single intratracheal injection of BLC (2.5 mg/kg body weight in 0.25 ml phosphate buffered saline), BLC + CRS group; 50 mg/kg CRS was administered 1 day before the intratracheal BLC injection and continued for 14 days orally. All animals were sacrificed at day 14th after BLC administration. The semiquantitative assessment of histopathological consisting of lung inflammation and collagen deposition, tissue levels of thiobarbituric acid reactive substances (TBARS), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reducted glutathione (GSH) were measured. BLC provoked histological changes consisting of alveolar congestion, increase connective tissue, infiltration, and the thickness of alveolar wall were detected significantly when compared to the control group (p ≤ 0.0001). CRS supplementation significantly restored these histological damages (p ≤ 0.0001). The level of tissue TBARS was increased with BLC (p < 0.01). Increased level of TBARS was significantly reversed by CRS administration. Also, BLC administration reduced tissue activities of SOD, GPx, CAT, and GSH in the lung tissue compared to control group (p < 0.01). Furthermore, the reduction in activities of CAT, SOD, and level of GSH were prevented by CRS supplementation (p < 0.01). In this study, we demonstrated for the first time that CRS significantly prevents BLC-induced lung inflammation and fibrosis in rats. Further studies are needed to assess the role of CRS in the treatment of lung inflammation and fibrosis.


antiinflammatory bleomycin chrysin pulmonary fibrosis idiopathic pulmonary fibrosis 


Conflict of Interest

The authors have no conflict of interest to declare. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.


  1. 1.
    Raghu, G., H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, et al. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.PubMedCrossRefGoogle Scholar
  2. 2.
    Gross, T.J., and G.W. Hunninghake. 2001. Idiopathic pulmonary fibrosis. New England Journal of Medicine 345: 517–525.PubMedCrossRefGoogle Scholar
  3. 3.
    Dedon, P.C., and I.H. Goldberg. 1992. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chemical Research in Toxicology 5: 311–332.PubMedCrossRefGoogle Scholar
  4. 4.
    Cottin, V. 2013. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respiratory Research 14(1): 5. doi: 10.1186/1465-9921-14- S1-S5.CrossRefGoogle Scholar
  5. 5.
    Mata, M., A. Ruíz, M. Cerdá, M. Martinez-Losa, J. Cortijo, F. Santangelo, A. Serrano-Mollar, A. Llombart-Bosch, and E.J. Morcillo. 2003. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. European Respiratory Journal 22(6): 900–905.PubMedCrossRefGoogle Scholar
  6. 6.
    Sogut, S., H. Ozyurt, F. Armutcu, et al. 2004. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. European Journal of Pharmacology 494: 213–220.PubMedCrossRefGoogle Scholar
  7. 7.
    Yildirim, Z., Y. Turkoz, M. Kotuk, et al. 2004. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11: 156–165.PubMedCrossRefGoogle Scholar
  8. 8.
    Kilic, T., H. Parlakpinar, A. Polat, E. Taslidere, N. Vardi, E. Sarihan, H. Ermis, and K. Tanbag. 2014. Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats. Inflammation. doi: 10.1007/s10753-014-9841-1.Google Scholar
  9. 9.
    Yildirim, Z., M. Kotuk, H. Erdogan, M. Iraz, M. Yagmurca, I. Kuku, and E. Fadillioglu. 2006. Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats. Journal of Pineal Research 40: 27–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Iraz, M., H. Erdogan, M. Kotuk, M. Yagmurca, T. Kilic, H. Ermis, E. Fadillioglu, and Z. Yildirim. 2006. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. Pharmacological Research 53: 310–316.PubMedCrossRefGoogle Scholar
  11. 11.
    Akgedik, R., S. Akgedik, H. Karamanli, S. Uysal, B. Bozkurt, D. Ozol, F. Armutcu, and Z. Yildirim. 2012. Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats. Inflammation 35(5): 1732–1741.PubMedCrossRefGoogle Scholar
  12. 12.
    Ermis, H., H. Parlakpinar, G. Gulbas, N. Vardi, A. Polat, A. Cetin, T. Kilic, and Z.A. Aytemur. 2013. Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats. Naunyn-Schmiedeberg’s Archives of Pharmacology. doi: 10.1007/s 00210-013-0908.PubMedGoogle Scholar
  13. 13.
    Sun, A., Q. Sun, and R. Liu. 2006. Spectroscopic investigation of the interaction between chrysin and bovine serum albumin. Chinese Journal of Analytical Chemistry 34: 243–246.CrossRefGoogle Scholar
  14. 14.
    Editorial committee of the pharmacopoeia of People's Republic of China, Pharmacopoeia of People's Republic of China (part one), Chemical Industry Press, Beijing, 1999, p. 48.Google Scholar
  15. 15.
    Wang, X., and M.E. Morris. 2007. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG 2. Drug Metabolism and Disposition 35: 268–274.PubMedCrossRefGoogle Scholar
  16. 16.
    Zheng, X., W.D. Meng, Y.Y. Xu, J.G. Cao, and F.L. Qing. 2003. Synthesis and anticancer effect of chrysin derivatives. Bioorganic and Medicinal Chemistry Letters 13: 881–884.PubMedCrossRefGoogle Scholar
  17. 17.
    Cho, H., C.W. Yun, and W.K. Park. 2004. Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives. Pharmacological Research 49: 37–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Rice-Evans, C.A. 2001. Flavonoid antioxidants. Current Medicinal Chemistry 8: 797–807.PubMedCrossRefGoogle Scholar
  19. 19.
    Ha, S.K., E. Moon, and S.Y. Kim. 2010. Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF-kappaB and JNK activations in microglia cells. Neuroscience Letters 485: 143–147.PubMedCrossRefGoogle Scholar
  20. 20.
    Mungunsukh, O., A.J. Griffin, Y.H. Lee, and R.M. Day. 2010. Bleomycin induces the extrinsic apoptotic pathway in pulmonary endothelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 298: 696–703.CrossRefGoogle Scholar
  21. 21.
    Pushpavalli, G., P. Kalaiarasi, C. Veeramani, and K.V. Pugalendi. 2010. Effect of chrysin on hepatoprotective and antioxidant status in D-galactosamine-induced hepatitis in rats. European Journal of Pharmacology 631: 36–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Yagi, K. 1998. Simple assay for the level of total lipid peroxides in serum or plasma. Methods in Molecular Biology 108: 101–106.PubMedGoogle Scholar
  23. 23.
    Sedlak, J., and R.H. Lindsay. 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Analytical Biochemistry 25: 192–205.PubMedCrossRefGoogle Scholar
  24. 24.
    Sun, Y., L.W. Oberley, and Y.A. Li. 1988. Simple method for clinical assay of superoxide dismutase. ClinChem 34: 497–500.Google Scholar
  25. 25.
    Aebi, H. 1974. Catalase. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 673–677. New York: Academic.CrossRefGoogle Scholar
  26. 26.
    Paglia, D.E., and W.N. Valentine. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Journal of Laboratory and Clinical Medicine 70(1): 158–169.Google Scholar
  27. 27.
    Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 193:265–275.Google Scholar
  28. 28.
    Sparreboom, A., M.C. Cox, M.R. Acharya, and W.D. Figg. 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. Journal of Clinical Oncology 22: 2489–2503.PubMedCrossRefGoogle Scholar
  29. 29.
    Middleton, E.J., C. Kandaswami, and T.C. Theoharides. 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacological Reviews 52: 673–751.PubMedGoogle Scholar
  30. 30.
    Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest 120: 617–624.PubMedCrossRefGoogle Scholar
  31. 31.
    Chaudhary, N.I., A. Schnapp, and J.E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. American Journal of Respiratory and Critical Care Medicine 35(173): 769–776.CrossRefGoogle Scholar
  32. 32.
    Mouratis, M.A., and V. Aidinis. 2011. Modeling pulmonary fibrosis with bleomycin. Current Opinion in Pulmonary Medicine 17: 355–361.PubMedCrossRefGoogle Scholar
  33. 33.
    Valko, M., D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser. 2007. Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry & Cell Biology 39: 44–84.CrossRefGoogle Scholar
  34. 34.
    MacNee, W., and I. Rahman. 1995. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 50: 53–58.CrossRefGoogle Scholar
  35. 35.
    Sheela, C.G., and K.T. Angusti. 1995. Antiperoxide effects of S-allyl cysteine sulphoxide isolated from Allium sativum Linn. and gugulipid in cholesterol diet fed rats. Indian Journal of Experimental Biology 33: 337–341.PubMedGoogle Scholar
  36. 36.
    Sultana, S., K. Verma, and R. Khan. 2012. Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress. Journal of Pharmacy and Pharmacology 64: 872–881.PubMedCrossRefGoogle Scholar
  37. 37.
    Wang, W., and R. Ballatori. 1998. Endogenous glutathione conjugates occurrence and biological functions. Pharmacological Reviews 32: 335–356.Google Scholar
  38. 38.
    Kinnula, V.L., J.D. Crapo, and K.O. Raivio. 1995. Generation and disposal of reactive oxygen metabolites in the lung. Laboratory Investigation 73: 3–19.PubMedGoogle Scholar
  39. 39.
    Liang, Y.-C., S.-H. Tsai, D.-C. Tsai, S.-Y. Lin-Shiau, and J.-K. Lin. 2001. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-by flavonoids in mouse macrophages. FEBS Letters 496: 12–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Sagrista, M.L., A.E. Garcia, M. Africa De Madariaga, et al. 2002. Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-l-cysteine and glutathione against free radical-induced lipid peroxidation. Free Radical Research 36: 329–340.PubMedCrossRefGoogle Scholar
  41. 41.
    Coward, W.R., G. Saini, and G. Jenkins. 2010. The pathogenesis of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease 4: 367–388.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Talat Kilic
    • 1
    Email author
  • Osman Ciftci
    • 2
  • Asli Cetin
    • 3
  • Hasan Kahraman
    • 4
  1. 1.Department of Pulmonary MedicineInonu University Faculty of Medicine, Turgut Ozal Medical CenterMalatyaTurkey
  2. 2.Department of Medical PharmacologyInonu University Faculty of MedicineMalatyaTurkey
  3. 3.Department of Embryology and HistologyInonu University Faculty of MedicineMalatyaTurkey
  4. 4.Department of Pulmonary MedicineSutcu İmam University Faculty of MedicineKahramanmaraşTurkey

Personalised recommendations